Xcout Intel
Artios
Artios Pharma is an independent biotechnology company headquartered at the Babraham Research Campus in Cambridge, United Kingdom, focused on discovering novel cancer therapies through DNA damage response mechanisms.
Subscribe to see Artios’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Artios at a glance
Artios is a biotechnology company headquartered in United Kingdom. It has raised at least $231.5M across the 3 funding rounds on record. Its most recent funding round, Series D, raised $115M in November 2025. Xcout tracks 12 named people at Artios, including Michael T. Andriole (President, Chief Executive Officer, and Director).
Artios leadership
- Michael T. AndriolePresident, Chief Executive Officer, and Director
- Christine SilversteinChief Financial Officer
- Graeme SmithChief Scientific Officer
- Ian SmithChief Medical Officer
- Jeremy B. FitchChief Business Officer
- Roy WareChief Manufacturing and Technology Officer
6 more named people on record for Artios, with roles, board committees and tenure — see the full roster →
Artios funding rounds
At least $231.5M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $115M | — | |
| Series B | $84M | 4 named | |
| Series A | $32.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Artios competitors
A few of Artios's closest competitors — see the full list of competitors and alternatives →
Apollo Therapeutics is a biopharmaceutical company with headquarters located in Cambridge, United Kingdom, alongside offices in Boston, Massachusetts. The company advances breakthrough science to build a portfolio of innovative therapeutics.
Mission Therapeutics is a drug discovery and development company recognized as a global leader in targeting deubiquitylating enzymes. Founded in 2011, the firm is based at the Babraham Research Campus in Cambridge, United Kingdom.
PhoreMost Ltd is a Cambridge, United Kingdom-based biotechnology and drug discovery company dedicated to turning scientific breakthroughs into life-changing cancer therapies.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Oxford BioTherapeutics is a clinical-stage oncology company focused on developing first-in-class cancer therapeutics with a proprietary pipeline. The company operates from locations in Oxford, United Kingdom, as well as San Jose, California, and Morristown, New Jersey, in the United States.
Cyteir Therapeutics, Inc. was a biotechnology company focused on developing novel cancer therapeutics leveraging synthetic lethality and DNA damage repair. Founded in 2012, the company was formerly publicly traded on Nasdaq before officially ceasing operations in 2024.
Get Artios's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Artios in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access